Acrivon Therapeutics (ACRV) Fundamental Analysis: Revenue, Earnings & Valuation

3.23 / 10

Netural

Fundamental analysis rates ACRV at 3.2/10, indicating weakness. Positive factors include PB‑ROE, cash‑to‑market value and inventory turnover, while Asset‑MV, revenue‑MV and gross margin lag. Tax‑to‑profit ratio is modest, suggesting selective consideration.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.25%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.16%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.25%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.15%

1M Return-0.63%

PB-ROE

Value-0.48

Score2/3

Weight15.37%

1M Return6.97%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.94%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.09%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.40%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight29.14%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight14.43%

1M Return5.94%

Is ACRV fundamentally strong?

ACRV scores 3.23/10 on fundamentals and holds a Fair valuation at present. Backed by its -53.86% ROE, 0.00% net margin, -0.76 P/E ratio, 0.52 P/B ratio, and 15.13% earnings growth, these metrics solidify its Netural investment rating.